{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:15:13Z","timestamp":1789568113676,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11864-025-01339-z","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:36:05Z","timestamp":1752831365000},"page":"754-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment"],"prefix":"10.1007","volume":"26","author":[{"given":"Pratik V.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"5","key":"1339_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","volume":"9","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, et al. Consensus recommendations from the 2024 lymphoma research foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2024;9(5):1213\u201329 (bloodadvances.2024014474).","journal-title":"Blood Adv"},{"key":"1339_CR2","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.","journal-title":"Front Cell Dev Biol"},{"issue":"23","key":"1339_CR3","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"15","key":"1339_CR4","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1038\/onc.2016.343","volume":"36","author":"CIE Smith","year":"2017","unstructured":"Smith CIE. From identification of the BTK kinase to effective management of leukemia. Oncogene. 2017;36(15):2045\u201353.","journal-title":"Oncogene"},{"issue":"5","key":"1339_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/bies.1062","volume":"23","author":"CI Smith","year":"2001","unstructured":"Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M. The tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays. 2001;23(5):436\u201346.","journal-title":"Bioessays"},{"issue":"6","key":"1339_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.4049\/jimmunol.145.6.1675","volume":"145","author":"D Campana","year":"1990","unstructured":"Campana D, Farrant J, Inamdar N, Webster AD, Janossy G. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J Immunol. 1990;145(6):1675\u201380.","journal-title":"J Immunol"},{"issue":"11","key":"1339_CR7","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MFM de Rooij","year":"2012","unstructured":"de Rooij MFM, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590\u20134.","journal-title":"Blood"},{"issue":"15","key":"1339_CR8","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1039\/D0SC06122K","volume":"12","author":"AT Voice","year":"2021","unstructured":"Voice AT, Tresadern G, Twidale RM, van Vlijmen H, Mulholland AJ. Mechanism of covalent binding of ibrutinib to Bruton\u2019s tyrosine kinase revealed by QM\/MM calculations. Chem Sci. 2021;12(15):5511\u20136.","journal-title":"Chem Sci"},{"issue":"4","key":"1339_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/leu.2017.304","volume":"32","author":"K Kondo","year":"2018","unstructured":"Kondo K, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway. Leukemia. 2018;32(4):960\u201370.","journal-title":"Leukemia"},{"issue":"1","key":"1339_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1339_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"25","key":"1339_CR12","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1016\/S2152-2650(24)01259-X","volume":"24","author":"J Burger","year":"2024","unstructured":"Burger J, et al. CLL-076 final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24:S342\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"1339_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112\u201320.","journal-title":"Blood"},{"issue":"16","key":"1339_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood.2023021959","volume":"143","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616\u201327.","journal-title":"Blood"},{"issue":"2","key":"1339_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, et al. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240\u201352.","journal-title":"J Pharmacol Exp Ther"},{"issue":"25","key":"1339_CR17","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849\u201361.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1339_CR18","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1200\/JCO.2022.40.16_suppl.7538","volume":"40","author":"W Jurczak","year":"2022","unstructured":"Jurczak W, et al. Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed\/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up. J Clin Oncol. 2022;40(16_suppl):7538\u20137538.","journal-title":"J Clin Oncol"},{"issue":"10232","key":"1339_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278\u201391.","journal-title":"Lancet"},{"issue":"Supplement 1","key":"1339_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2023-174750","volume":"142","author":"JP Sharman","year":"2023","unstructured":"Sharman JP, et al. Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN. Blood. 2023;142(Supplement 1):636\u2013636.","journal-title":"Blood"},{"issue":"31","key":"1339_CR21","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1339_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142(8):687\u201399.","journal-title":"Blood"},{"key":"1339_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2147\/DDDT.S250823","volume":"15","author":"JM Rhodes","year":"2021","unstructured":"Rhodes JM, Mato AR. Zanubrutinib (BGB-3111), a second-generation selective covalent inhibitor of Bruton\u2019s tyrosine kinase and its utility in treating chronic lymphocytic leukemia. Drug Des Devel Ther. 2021;15:919\u201326.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1339_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol"},{"issue":"S3","key":"1339_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969460.15364.af","volume":"7","author":"T Munir","year":"2023","unstructured":"Munir T, et al. P639: Zanubrutinib (zanu) vs bendamustine + rituximab (Br) in patients (pts) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (cll\/sll): extended follow-up of the sequoia study. HemaSphere. 2023;7(S3): e15364af.","journal-title":"HemaSphere"},{"issue":"4","key":"1339_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"1339_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(1):21.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1339_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"1339_CR29","first-page":"62","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62\u201372.","journal-title":"Blood"},{"issue":"1","key":"1339_CR30","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/s41467-020-16128-5","volume":"11","author":"DP Duarte","year":"2020","unstructured":"Duarte DP, et al. Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. Nat Commun. 2020;11(1):2319.","journal-title":"Nat Commun"},{"issue":"7_Supplement","key":"1339_CR31","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/1538-7445.AM2023-2780","volume":"83","author":"JA Ballard","year":"2023","unstructured":"Ballard JA, et al. Abstract 2780: unique pharmacodynamic properties conferred by differential binding to BTK, pirtobrutinib vs covalent inhibitors. Cancer Res. 2023;83(7_Supplement):2780\u20132780.","journal-title":"Cancer Res"},{"key":"1339_CR32","doi-asserted-by":"publisher","unstructured":"Woyach J et al. Pirtobrutinib in post-cBTKi CLL\/SLL: ~30 months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study. Blood. 2023;142(Supplement 1):325. https:\/\/doi.org\/10.1182\/blood-2023-185852.","DOI":"10.1182\/blood-2023-185852"},{"issue":"24","key":"1339_CR33","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286\u201394.","journal-title":"N Engl J Med"},{"issue":"5","key":"1339_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3324\/haematol.2022.281402","volume":"108","author":"AP Bye","year":"2023","unstructured":"Bye AP, et al. Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica. 2023;108(5):1429\u201335.","journal-title":"Haematologica"},{"issue":"1","key":"1339_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","volume":"14","author":"D Gu","year":"2021","unstructured":"Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"1339_CR36","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood.V128.22.2032.2032","volume":"128","author":"LL Neuman","year":"2016","unstructured":"Neuman LL, et al. First-in-human phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of the noncovalent bruton tyrosine kinase (BTK) inhibitor SNS-062 in healthy subjects. Blood. 2016;128(22):2032\u20132032.","journal-title":"Blood"},{"issue":"4","key":"1339_CR37","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2021.280061","volume":"107","author":"JN Allan","year":"2022","unstructured":"Allan JN, et al. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022;107(4):984\u20137.","journal-title":"Haematologica"},{"issue":"10","key":"1339_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood.2024026672","volume":"145","author":"CS Tam","year":"2025","unstructured":"Tam CS, Balendran S, Blombery P. Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors. Blood. 2025;145(10):1005\u20139.","journal-title":"Blood"},{"issue":"6682","key":"1339_CR39","doi-asserted-by":"publisher","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya S, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science. 2024;383(6682):eadi5798.","journal-title":"Science"},{"issue":"10","key":"1339_CR40","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144(10):1061\u20138.","journal-title":"Blood"},{"issue":"Supplement_1","key":"1339_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2019-125488","volume":"134","author":"SM Handunnetti","year":"2019","unstructured":"Handunnetti SM, et al. BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib. Blood. 2019;134(Supplement_1):170\u2013170.","journal-title":"Blood"},{"issue":"19","key":"1339_CR42","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","volume":"7","author":"J Qi","year":"2023","unstructured":"Qi J, et al. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors. Blood Adv. 2023;7(19):5698\u2013702 (American Society of Hematology).","journal-title":"Blood Adv"},{"issue":"8","key":"1339_CR43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735\u201343.","journal-title":"N Engl J Med"},{"key":"1339_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00894","volume":"10","author":"L Sedlarikova","year":"2020","unstructured":"Sedlarikova L, Petrackova A, Papajik T, Turcsanyi P, Kriegova E. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020;10: 894.","journal-title":"Front Oncol"},{"issue":"9","key":"1339_CR45","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"C Moreno","year":"2022","unstructured":"Moreno C, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III illuminate trial. Haematologica. 2022;107(9):2108\u201320.","journal-title":"Haematologica"},{"issue":"3","key":"1339_CR46","first-page":"121","volume":"22","author":"J Sharman","year":"2024","unstructured":"Sharman J. Six-year update of the ELEVATE-TN study on acalabrutinib. Clin Adv Hematol Oncol. 2024;22(3):121\u20132.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"1339_CR47","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/bjh.17984","volume":"196","author":"JN Allan","year":"2022","unstructured":"Allan JN, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196(4):947\u201353.","journal-title":"Br J Haematol"},{"issue":"10","key":"1339_CR48","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O\u2019Brien","year":"2016","unstructured":"O\u2019Brien S, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409\u201318.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1339_CR49","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","volume":"3","author":"FT Awan","year":"2019","unstructured":"Awan FT, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553\u201362.","journal-title":"Blood Adv"},{"issue":"9","key":"1339_CR50","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","volume":"106","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364\u201373.","journal-title":"Haematologica"},{"issue":"1","key":"1339_CR51","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","volume":"10","author":"M Shadman","year":"2023","unstructured":"Shadman M, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35\u201345.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1339_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390(4):326\u201337.","journal-title":"N Engl J Med"},{"issue":"7","key":"1339_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1(7): EVIDoa2200006.","journal-title":"NEJM Evid"},{"issue":"34","key":"1339_CR54","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853\u201365.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1339_CR55","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392(8):748\u201362.","journal-title":"N Engl J Med"},{"key":"1339_CR56","unstructured":"NCCN Clinical Practice Guidelines in Oncology\/Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Nccn.org. 2025. [Online]. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed 03 Apr 2025."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01339-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01339-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01339-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:04:52Z","timestamp":1756933492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01339-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01339-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}